Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Takahiro Yamashiro"'
Publikováno v:
Life science alliance. 6(2)
Disrupted in renal carcinoma 2 (DIRC2) has gained interest because of its association with the development of renal cancer and cosegregation with a chromosomal translocation. It is a member of the SLC49 family (SLC49A4) and is considered to be an ele
Publikováno v:
J Biol Chem
The Journal of biological chemistry, vol 295, iss 50
The Journal of biological chemistry, vol 295, iss 50
SLC19A2 and SLC19A3, also known as thiamine transporters (THTR) 1 and 2, respectively, transport the positively charged thiamine (vitamin B1) into cells to enable its efficient utilization. SLC19A2 and SLC19A3 are also known to transport structurally
Publikováno v:
The Journal of biological chemistry. 298(8)
Recent studies have shown that human solute carrier SLC19A3 (hSLC19A3) can transport pyridoxine (vitamin B6) in addition to thiamine (vitamin B1), its originally identified substrate, whereas rat and mouse orthologs of hSLC19A3 can transport thiamine
Autor:
Hiroaki Yuasa, Katsuhisa Inoue, Risa Takenaka, Junji Furukawa, Takahiro Yamashiro, Tomoya Yasujima, Yosuke Hishikawa, Kinya Ohta
Publikováno v:
Journal of Pharmaceutical Sciences. 109:2622-2628
Equilibrative nucleobase transporter 1 (ENBT1/SLC43A3) has recently been identified as a purine-selective nucleobase transporter. Although it is highly expressed in the liver, its role in nucleobase transport has not been confirmed yet in hepatocytes
Publikováno v:
Drug metabolism and pharmacokinetics. 44
The thiamine transporters, SLC19A2 and SLC19A3, have recently been shown to transport pyridoxine in addition to thiamine, the originally identified substrate, in our study on human orthologs. Based on these results, we characterized the rat and mouse
Publikováno v:
Life Science Alliance; Feb2023, Vol. 6 Issue 2, p1-11, 11p
Publikováno v:
Drug Metabolism and Pharmacokinetics. 43:100443
Orotate, a nutritional compound typically utilized as an intermediate in pyrimidine synthesis, has been suggested to undergo renal reabsorption. However, the detailed mechanisms involved in the process remain unclear, with only urate transporter 1 (U
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Human proton-coupled folate transporter (hPCFT/SLC46A1) has recently been found to be inhibited by myricetin by a sustained mechanism, raising a concern that the inhibition might lead to malabsorption of folates in the intestine, where hPCFT works fo
Autor:
Tatsuya Ikari, Ikumi Imajo, Yoshihide Mori, Takahiro Yamashiro, Hiroyuki Nakano, Tomoko Kitsuki
Publikováno v:
Japanese Journal of Oral and Maxillofacial Surgery. 64:207-212
Publikováno v:
Drug Metabolism and Pharmacokinetics. 32:311-314
Myricetin is a flavonoid that inhibits human proton-coupled folate transporter (hPCFT) in a transient manner, in which inhibition is manifested in its presence, and also in a sustained manner, in which inhibition induced in its presence persists afte